On January 4, 2021 Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, reported that Eric Ostertag, M.D., Ph.D., Poseida Therapeutics’ Chief Executive Officer, will participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event taking place from January 11-14, 2021 (Press release, Poseida Therapeutics, JAN 4, 2021, View Source [SID1234573447]). In addition, management will be available for one-on-one meetings with investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for on-demand viewing on the Investors & Media Section of the Poseida website, www.poseida.com, beginning Monday, January 11, 2021 at 7:00 a.m. ET and will be available for approximately 30 days.

On January 4, 2021 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021 (Press release, Selecta Biosciences, JAN 4, 2021, View Source [SID1234573396]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 6 a.m. EST on Monday, January 11, 2021.

A webcast will also be available in the Investors & Media section of the company’s website at www.selectabio.com.

On January 4, 2021 X-Chem Inc. (X-Chem), the global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, reported that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has licensed a second drug discovery program from X-Chem (Press release, X-Chem, JAN 4, 2021, View Source [SID1234573413]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the parties’ multi-target Drug Discovery Research and License Collaboration, Otsuka exercised the option to exclusively license this additional program, which comprises a promising highly-specific novel small molecule drug lead for a very challenging target. The license is a direct result of X-Chem screening its DNA-encoded libraries containing hundreds of billions of drug-like small molecules, and using its advanced proprietary informatics platform to identify novel drug leads for the Otsuka target. Otsuka is solely responsible for the conduct of clinical trials with drug candidates derived from licensed compounds, and retains exclusive rights to globally commercialize any resulting products.

"X-Chem is proud to issue our second compound license to Otsuka," said Matt Clark, CEO of X-Chem. "Our partnership with Otsuka has been a success due to the collaborative engagement and rigorous determination of the joint research teams, who achieved our mutual goal of identifying hit compounds for extremely difficult-to-drug targets. We look forward to continued engagement with Otsuka in the coming years as X-Chem continues to expand our leadership position in the drug discovery field."

On January 4, 2021 Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. ET (Press release, Scholar Rock, JAN 4, 2021, View Source [SID1234573431]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at View Source An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

On January 4, 2021 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11th at 7:30 a.m. EST (Press release, PTC Therapeutics, JAN 4, 2021, View Source [SID1234573448]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics’ website at www.ptcbio.com and will be archived for 30 days following the presentation. It is recommended that users connect to PTC’s website several minutes prior to the start of the webcast to ensure a timely connection.